• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Sigma-Aldrich Introduces MISSION(R) LentiPlex(TM) Pooled shRNA Libraries to Enable Rapid Whole Genome Screening in Primary Cells, Stem Cells or Tumor Cells

Posted on: Tuesday, 3 March 2009, 07:15 CST

ST. LOUIS, March 3 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) today announced the global release of the MISSION(R) LentiPlex(TM) Pooled Human and Murine shRNA Libraries (http://www.sigma-aldrich.com/lentiplex). Using the shRNA collections of The RNAi Consortium (TRC), the MISSION LentiPlex Pooled shRNA Libraries enable rapid, genome-wide RNAi screening at the bench-top level in a convenient and powerful, pooled lentiviral format. As a member of both TRC-1 and TRC-2 collaborations, Sigma-Aldrich is the exclusive commercial source for access to TRC shRNA libraries in lentiviral format.

The MISSION LentiPlex Pooled shRNA Libraries were developed from the entire TRC-1 human and mouse collections of more than 158,000 shRNA constructs targeting approximately 16,000 human genes and approximately 16,000 mouse genes. Combining Sigma-Aldrich's high-throughput lentiviral production methodologies with the pooled library format enables researchers to perform genome-wide RNAi screens on various cell types, rapidly and efficiently discovering new targets without a large investment in infrastructure.

"Sigma-Aldrich is committed to providing customers powerful and unique screening formats that fully leverage the content of TRC," said Tim Fleming, Director of Global Commercial Marketing at Sigma-Aldrich. "The pooled lentiviral format of this product is expected to make the discovery potential of the TRC collection accessible to any researcher with minimal reagent, time or capital equipment investment."

LentiPlex enables researchers to screen for novel phenotypes in relevant cell lines and study gene function and disease, both in standard cell lines and difficult cell types such as primary, non-dividing, growth-arrested or terminally differentiated cells that are typically resistant to standard siRNA transfection or other viral delivery systems. In addition, Sigma-Aldrich's shRNA libraries include a U6 promoter for shRNA expression in a wide variety of cell lines including embryonic stem cells. These characteristics mean researchers can now conduct high quality pooled shRNA screens in the cell lines of their choice.

The MISSION LentiPlex Pooled shRNA Libraries add to Sigma-Aldrich's suite of MISSION shRNA products, which include the MISSION TRC-1 shRNA human (MISSION TRC-Hs1.0) and murine (MISSION TRC-Mm1.0) collections of whole genome arrayed libraries, gene family sets or individually prepared clones in glycerol, purified DNA or lentiviral formats. For more information on the MISSION LentiPlex Pooled shRNA Library, please visit http://www.sigma-aldrich.com/lentiplex.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 37 countries and has 7,900 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

Sigma-Aldrich, MISSION and LentiPlex are registered trademarks of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co.

SOURCE Sigma-Aldrich

Source: PR Newswire

More News in this Category